Abion Announces Barvamekip Phase 2 Clinical Trial Cutoff at US ASCO

Abion announced on the 8th that it will present the cutoff results of the Phase 2 clinical trial of Babamekip (ABN401) at the American Society of Clinical Oncology (ASCO 2024).

ASCO is one of the world's top three cancer conferences, along with the American Association for Cancer Research (AACR) and the European Society for Medical Oncology (ESMO). It will be held from May 31 to June 4 (local time) at McCormick Place in Chicago, USA.

Abion plans to deliver an oral presentation on the Phase 2 clinical trial results of Babamekip at the 'IET (Industry Expert Theater)' session, which is a corporate expert presentation session. IET is a presentation program where global pharmaceutical companies disclose their research and development pipelines or clinical results.

Babamekip is a tyrosine kinase inhibitor (TKI) targeting c-MET mutant cancers. c-MET induces cancer cell growth and angiogenesis, and Babamekip targets c-MET, which is a major resistance cause of existing treatments for non-small cell lung cancer. The first interim results of the Phase 2 trial were disclosed in October last year, confirming efficacy and excellent safety. The latest updated results of the Phase 2 trial will be revealed at ASCO.

A company representative said, "It is meaningful to present additional cutoff data of the Phase 2 trial at a global conference attended by international cancer experts and R&D personnel," adding, "Based on the encouraging results, we expect accelerated global clinical patient recruitment and license-out (LO)."